Lihat Juga

• Figure 2 from: Shebeko S, Zupanets I, Otrishko I (2020) Efficacy of the N-acetylglucosamine in experimental therapy of chronic kidney disease. Pharmacia 67(4): 253-259. https://doi.org/10.3897/pharmacia.67.e38078
  oleh: Shebeko, Sergii, et al.
  Terbitan: (2020)
• Figure 4 from: Shebeko S, Zupanets I, Otrishko I (2020) Efficacy of the N-acetylglucosamine in experimental therapy of chronic kidney disease. Pharmacia 67(4): 253-259. https://doi.org/10.3897/pharmacia.67.e38078
  oleh: Shebeko, Sergii, et al.
  Terbitan: (2020)
• Figure 3 from: Shebeko S, Zupanets I, Otrishko I (2020) Efficacy of the N-acetylglucosamine in experimental therapy of chronic kidney disease. Pharmacia 67(4): 253-259. https://doi.org/10.3897/pharmacia.67.e38078
  oleh: Shebeko, Sergii, et al.
  Terbitan: (2020)
• Efficacy of the N-acetylglucosamine in experimental therapy of chronic kidney disease
  oleh: Shebeko, Sergii, et al.
  Terbitan: (2020)
• Figure 1 from: Susilawati NM, Halimah E, Saidah S (2021) Pharmacists' strategies to detect, resolve, and prevent DRPs in CKD patients. Pharmacia 68(3): 619-626. https://doi.org/10.3897/pharmacia.68.e65136
  oleh: Susilawati, Ni Made, et al.
  Terbitan: (2021)